Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with ...

Nevertheless, this deceleration is expected to be somewhat balanced by an increase in utilization rates. The company's growth prospects are further anticipated to be supported by the introduction of ...

The company's growth prospects are further anticipated to be supported by the introduction of the Zephyr valve in Japan and the commercialization of Aeriseal in 2026. Despite optimism surrounding ...

He led execution of key clinical trials leading to FDA approval of the Zephyr Valves in the US. Before Pulmonx, Narinder was Vice President, Clinical Strategy and Medical Affairs–Pulmonary at ...